Account
Watchlists
Bookmarks
Pricing
Market Cap
₹ 16,211 Cr
P/E
10.54
Bearish
1
Neutral
8
Bullish
5
Bearish
1
Neutral
8
Bullish
37
Bearish
0
Neutral
0
Bullish
32
No. of Analysts
1Y Price Target
Q3 EPS Estimate
Q3 Revenue Estimate
Price, EPS and Revenue Projections
Strong Buy
2
Buy
1
Hold
5
Sell
4
Strong Sell
4
updated on
Dec 03, 2025
Get In-depth insights on EPS and Revenue forecasts
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Natco Pharma Limited is a pharmaceutical company specializing in the development, manufacturing, and marketing of niche therapeutic products, focusing on complex generics and high-potency APIs.
The company has a strong R&D focus with significant investment in bioequivalence studies and Para-IV filings, enhancing its competitive edge in challenging patents for high-value drugs.
Recent acquisitions, such as Dash Pharmaceuticals in the USA and stakes in Adcock Ingram in South Africa, highlight Natco's strategy to diversify and expand its international presence.
Strategic partnerships with companies like Viatris and Alvogen facilitate broader market reach and distribution, especially in regulated markets such as the USA and Canada.
The company's focus on oncology products and complex generics positions it well within the biotech and pharmaceutical industry, capable of sustaining growth through innovation and market expansion.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
16,211 Cr
High Risk
10.5
30.8
—
1.9
1,490.00
660.05
Sales CAGR
1Y
10.77%
3Y
32.31%
5Y
17.99%
10Y
16.21%
Profit CAGR
1Y
35.66%
3Y
136.94%
5Y
31.28%
10Y
29.83%
ROE
TTM
17.79%
3Y
21.75%
5Y
17.21%
10Y
17.60%
ROCE
TTM
21.15%
3Y
26.27%
5Y
20.90%
10Y
21.77%
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Performance
UNDER PERFORMER
Valuation
UNDERVALUED
Growth
EXCEPTIONAL
Profitability
HIGH MARGIN
Technicals
Bullish
Risk
MODERATE RISK
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1341.00 | 21,770 Cr | 308.70 | 4.77 | 0.00 | 1.54 | 4.05 | -0.60 | |
531.75 | 20,289 Cr | 59.06 | 5.36 | 0.00 | 8.61 | 9.19 | 5.63 | |
905.10 | 16,211 Cr | 10.54 | 1.87 | 0.66 | 17.79 | 21.15 | 14.73 | |
1362.65 | 14,256 Cr | 44.00 | 7.80 | 0.64 | 17.73 | 23.48 | 15.99 | |
571.00 | 13,864 Cr | 27.14 | 3.48 | 0.26 | 12.88 | 13.37 | 7.39 | |
913.30 | 11,177 Cr | 21.07 | 3.71 | 0.55 | 17.59 | 23.34 | 14.58 | |
550.00 | 9,537 Cr | 27.07 | 7.59 | 0.22 | 28.06 | 37.35 | 23.07 |
